China's National Medical Products Administration (NMPA) awarded a marketing approval to Simcere Pharmaceutical Group's (HKG:2096) neuro symptoms drug, according to a Sunday filing with the Hong Kong bourse.
Sanbexin sublingual tablets are used to reduce brain cell injury or impairment caused by Acute Ischemic Stroke (AIS), the filing added.